Table 3.

The associations between preoperative CRP, CYFRA 21-1, and clinicopathologic parameters (N = 130)

	CRP (−), CYFRA 21-1 (−)	CRP (−),CYFRA 21-1 (+)	CRP (+),CYFRA 21-1 (−)	CRP (+),CYFRA 21-1 (+)
	(n (%))	(n (%))	(n (%))	(n (%))	P value
Tumor stage
Earlya (n = 45)	33 (73.3)	7 (15.6)	5 (11.1)	0 (0.0)	0.009 e
Advancedb (n = 85)	52 (61.2)	1 (1.2)	22 (25.9)	10 (11.8)
Pathologic N stage
N0 (n = 68)	47 (69.1)	7 (10.3)	12 (17.6)	2 (2.9)	0.012 e
N1 (n = 25)	18 (72.0)	0 (0.0)	7 (28.0)	0 (0.0)
N2 (n = 37)	20 (54.1)	1 (2.7)	8 (21.6)	8 (21.6)
Nodal status
(−) metastasis, (−) ECS (n = 68)	47 (69.1)	7 (10.3)	12 (17.6)	2 (2.9)	0.006 e
(+) metastasis, (−) ECS (n = 23)	18 (78.3)	0 (0.0)	5 (21.7)	0 (0.0)
(+) metastasis, (+) ECS (n = 39)	20 (51.3)	1 (2.6)	10 (25.6)	8 (20.5)
Differentiation
Well (n = 32)	20 (62.5)	1 (3.1)	9 (28.1)	2 (6.2)	0.734
Moderate (n = 80)	55 (68.8)	6 (7.5)	13 (16.2)	6 (7.5)
Poor (n = 18)	10 (55.6)	1 (5.6)	5 (27.8)	2 (11.1)
Pathologic tumor status
Earlyc (n = 74)	56 (75.7)	8 (10.8)	10 (13.5)	0 (0.0)	<0.001 e
Advancedd (n = 56)	29 (51.8)	0 (0.0)	17 (30.4)	10 (17.9)
Skin invasion
No (n = 117)	80 (68.4)	8 (6.8)	22 (18.8)	7 (6.0)	0.006 e
Yes (n = 13)	5 (38.5)	0 (0.0)	5 (38.5)	3 (23.1)
Bone invasion
No (n = 105)	75 (71.4)	8 (7.6)	16 (15.2)	6 (5.7)	0.001 e
Yes (n = 25)	10 (40.0)	0 (0.0)	11 (44.0)	4 (16.0)
Tumor depth ≥10 mm
No (n = 60)	47 (78.3)	6 (10.0)	7 (11.7)	0 (0.0)	<0.001 e
Yes (n = 70)	38 (54.3)	2 (2.9)	20 (28.6)	10 (14.3)

CRP (−) CRP level <5.0 mg/L, CRP (+) CRP level ≥5.0 mg/L, CYFRA 21-1 (−) CYFRA 21-1 <3.3 ng/mL, CYFRA 21-1 (+) CYFRA 21-1 ≥3.3 ng/mL, ECS extra-capsular spread

^aStage I–II

^bStage III–IV

^cT1–T2

^dT3–T4

^eFisher’s exact test